IGFBP3 and cancer: Kang et al. demonstrated that cancer-associated fibroblast (CAF)-derived extracellular vesicles carrying miR-876-3p can modulate CDDP resistance in OSCC by targeting insulin-like growth factor binding protein 3 (IGFBP3)[57].